The future of biomedical innovation depends in part on a new trend for all players in biomedical innovation to work together for the common goal, say 2 MIT researchers
It’s a long, expensive, risky road to turn a scientific breakthrough into a treatment that can help patients. Fewer organizations are trying to tackle the challenges alone, says a new paper from MIT researchers published August 28 in the journal Science Translational Medicine.
An essential new way to move discoveries forward has emerged in the form of multi-stakeholder collaborations involving three or more different types of organizations, such as drug companies, government regulators and patient groups, write Magdalini Papadaki, a research associate, and Gigi Hirsch, a physician-entrepreneur and executive director of the MIT Center for Biomedical Innovation.
The authors are calling for a new “science of collaboration” to learn what works and doesn’t work; to improve how leaders can design, manage and evaluate collaborations; and to help educate and train future leaders with the necessary organizational and managerial skills.
“Getting new, better, affordable drugs to the right patients faster involves a series of historically independent decisions made by different players or stakeholders,” says Hirsch. The system is uncoordinated, takes too long, and costs too much. In some cases, the drug—such as new antibiotics for life-threatening resistant infections—may never become available.
“One of the interesting paradoxes of biomedical innovation is increasingly going to be that even though we have the scientific knowledge required to provide potentially better treatments for patients—or even to prevent disease in those who are at high risk—we may be unable to help patients benefit from them anytime soon,” she says.
To help change this scenario, in the last decade, thousands of researchers, pharmaceutical and biotechnology companies, government regulators, payers, clinicians and patients have come together in more than 100 multi-stakeholder collaborations to solve some specific shared problem standing in the way of finding a cure or a better diagnostic approach.
“Multi-stakeholder collaborations provide the opportunity to create an environment that allows for new kinds of interactions among the players,” Hirsch says. The largest multi-stakeholder effort, the European Union’s Innovative Medicines Initiative (IMI) began in 2008 and has established more than 40 consortia with financial and in-kind investments totaling €2 billion. Some projects focus on specific health issues, such as Alzheimer’s disease, chronic pain, diabetes and obesity. Others tackle bigger issues, such as drug and vaccine safety and the use of stem cells for drug discovery. The success has led to a proposal to extend the effort for 10 years and €3.5 billion. Last year, the U.S. President’s Council of Advisors on Science and Technology (PCAST) recommended the U.S. form something similar.
“The prevalence of multi-stakeholder initiatives reflects a continued optimism about the value of this collaboration approach for addressing biomedical innovation bottlenecks,” the authors write in the paper. “Although the need for collaboration is no longer in question, it is worth noting the importance of this development. A willingness to share proprietary data among industry competitors represents a dramatic shift in the culture of the historically highly competitive pharmaceutical industry.”
The article reviews the history of collaborations beginning with HIV/AIDS. By the early 2000s, multi-stakeholder collaborations proliferated to address the need for important tools, such as biomarkers, that require preclinical data sharing. Since then, they have reached to encompass later stages in product development, including manufacturing, reimbursement and post-market monitoring.
Some people involved in multi-stakeholder consortia are concerned about redundancy, inefficiency and lack of productivity of some collaborative efforts, all contributing to a sense of “consortium fatigue,” the researchers write.
In a newer trend, funders and participants are seeking a smaller number of strategically coordinated initiatives that will reliably address critical gaps, Hirsch and Papadaki write. They cite the example of TransCelerate BioPharma, a group of 10 major pharmaceutical companies that came together to share and direct resources toward selected priorities in order to improve the efficiency of drug development, such as clinical trial site qualification standards.
The authors propose a rigorous evidence-based approach (the science of collaboration) to figure out what works and doesn’t work in collaborations. They recommend early steps in this new field and structuring the research to help learn from the past but also to evolve effectively as new innovation challenges emerge.
The Latest Bing News on:
Science of collaboration
- World's First Wooden Satellite Will Launch By End Of 2021on April 22, 2021 at 9:34 am
When you think of creating an object that will travel 40,000 kilometers per hour (25,000 miles per hour) as it pushes up and out of the atmosphere, ready t ...
- Sir David Attenborough to narrate new Netflix documentary Breaking Boundaries: The Science of our Planeton April 22, 2021 at 9:23 am
Sir David Attenborough is to narrate an upcoming Netflix documentary titled Breaking Boundaries: The Science of our Planet. The film, which is due to be released on the streaming platform later this ...
- RIC School of Nursing Accepts the Nurses Climate Challengeon April 22, 2021 at 8:09 am
The Rhode Island College School of Nursing recently adopted the Nurses Climate Challenge, a national campaign and collaboration between Health Care Without Harm, an international nonprofit that ...
- A new study identifies interleukin 11 as a marker of cancer-associated fibroblastson April 22, 2021 at 8:01 am
IL-11 is known to promote the development of colorectal cancer in humans and mice, but when and where IL-11 is expressed during cancer development is unknown. "To address these questions ...
- Vyant Bio, Inc., Ordaōs Bio, and Cellaria, Inc. Announce Collaboration to Design and Qualify Biomarker-Specific Small Protein Therapeuticson April 22, 2021 at 7:00 am
New collaboration mitigates risk in drug discovery process with artificial intelligence and in vitro “avatar”clinical trialsCHERRY HILL, N.J., ...
- Vertex and Obsidian Therapeutics Establish Collaboration to Discover Novel Therapies That Regulate Gene Editingon April 22, 2021 at 5:01 am
Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) and Obsidian Therapeutics announced today that the two companies have entered into a strategic research collaboration and licensing agreement focused ...
- Opinion: Gulf of Mexico Hypoxia Task Force is committed to collaboration and conservationon April 22, 2021 at 3:37 am
That’s why the 12 states bordering the Mississippi and Ohio Rivers, five federal agencies, and the National Tribal Water Council formed the Gulf of Mexico Hypoxia Task Force, or HTF. While each state ...
- Theme of 5th World Intelligence Congress unveiledon April 22, 2021 at 2:14 am
The 5th World Intelligence Congress scheduled in Tianjin from May 20 to 23 will be themed "New Era of Intelligence: Empowering New Development, Fostering New Pattern," according to the organizing ...
- Katrin Heitmann elected spokesperson for LSST Dark Energy Science Collaborationon April 20, 2021 at 7:00 am
Dark Energy Science Collaboration (DESC) is one of the leading efforts. "I am very honored to be elected as spokesperson for this international collaboration. It is a tremendous responsibility and, at ...
- Gold digger: Neural networks at the nexus of data science and electron microscopyon April 19, 2021 at 9:00 pm
Researchers at the Max Planck Florida Institute for Neuroscience used machine learning to develop a new, fully automated way to search and identify gold particles markers in electron micrographs with ...
The Latest Google Headlines on:
Science of collaboration
The Latest Bing News on:
- Wuxi Strives to Build a World-class Biomedical Industry Chainon April 22, 2021 at 4:06 am
From April 21 to 23, the 2021 Taihu Bay Future Healthcare Conference was held in Wuxi, China. More than 160 experts including Hejie, Fan Chunhai and many ...
- After coronavirus vaccine failures, France laments the state of its biomedical R&Don April 21, 2021 at 1:15 pm
After coronavirus vaccine failures, France laments the state of its R&D. Apr. 21, 2021 , 4:15 PM. On 25 January, as France’s third pandemic wav ...
- STEMart Announces Medical Device Design Services for the Biomedical Industryon April 21, 2021 at 12:11 am
STEMart, a provider of integrated medical device CRO services dedicated to medical device and diagnostic clinical development, recently announces medical device design services for life science and ...
- Cytocom, Inc. Appoints Stephen Wilson, Ph.D., as Head of Global Innovationon April 20, 2021 at 4:30 am
Cytocom, Inc. (Cytocom), a leading biopharmaceutical company creating next generation immune therapies built around proprietary discovery ...
- Texas County commits $75 million to biomedical venture fundon April 19, 2021 at 7:25 am
The $37.5 billion Texas County & District Retirement System, Austin, committed $75 million to Vida Ventures III, managed by Vida Ventures Advisors, a transaction report showed. The firm specializes in ...
- Amrita varsity to set up 50 innovation labs in its campuseson April 18, 2021 at 3:44 pm
Amrita Vishwa Vidyapeetham has announced a grant of Rs 100 crore to set up 50 state-of-the-art ‘New Discovery and Innovation Labs’ at its campuses across India.
- Three teams selected to receive the first awards from Dartmouth Innovations Accelerator for Canceron April 18, 2021 at 11:40 am
Three teams of Dartmouth researchers have been selected to receive the first awards from the Dartmouth Innovations Accelerator for Cancer.
- Biomedical engineering student graduates with five prestigious graduate offerson April 15, 2021 at 11:23 am
The strength of UAB is its people. Students, faculty and staff are engaged in their work and aim to positively impact the world.
- Global Biomedical and ICT Convergence Markets Report 2021: Market is Expected to Reach $64 Billion by 2026on April 15, 2021 at 1:33 am
The "Biomedical and ICT Convergence Market by Technology, Solution and Region 2021-2026" report has been added to ResearchAndMarkets.com's offering. This report evaluates the market for convergence ...
- Evotec Launches 'BeLAB2122', Translating Academic Innovation from Leading German Life Science Region in Collaboration with Bristol Myers Squibbon April 12, 2021 at 11:00 pm
LAB2122 brings together leading academic institutions from the Rhine-Main-Neckar region of Germany with the goal of efficiently advancing first-in-class therapeutic options across all therapeutic ...